Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT05579327Phase 3Completed
Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 Deficiency
PrincipalinvestigatorStart date: 2023-07-21

Research Network

Collaboration Network

2 collaborators·1 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

W. E. Visser, MD

Erasmus Medical Center

Moderately Similar
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 DeficiencyMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Egetis Therapeutics AB (publ)Premier Research+1 more
Collaborated on 1 trial
Similarity Score34%

Andrew Bauer, MD

Children's Hospital of Philadelphia

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Rare Thyroid Therapeutics International AB
Similarity Score20%

Heiko Krude

Charité - Universitätsmedizin Berlin Institut fur experimental paediatrische endokrinologie

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Rare Thyroid Therapeutics International AB
Similarity Score20%

W.E. Visser, MD, PhD

Erasmus Medical Center

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Rare Thyroid Therapeutics International AB
Similarity Score20%

Lindsey Nicol

Oregon Health& Science University (OHSU) Doernbecher Childrens Hospital

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Rare Thyroid Therapeutics International AB
Similarity Score20%

Kristina Sjöblom Nygren, MD

Rare Thyroid Therapeutics International AB

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Rare Thyroid Therapeutics International AB
Similarity Score20%

Mark Larkin, PhD

Vitaccess Limited

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Rare Thyroid Therapeutics International AB
Similarity Score20%

Jan Lebl

Charles University and Motol University Hospital

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 (MCT8) Deficiency

Worked with same sponsors:

Rare Thyroid Therapeutics International AB
Similarity Score20%

Amnon Zung, MD

Kaplan Medical Center, affiliated with the Hebrew University of Jerusalem, Israel

Related
1 trials

Shared therapeutic areas:

Monocarboxylate Transporter 8 Deficiency
Similarity Score10%

Heiko Krude, MD

Charite University, Berlin, Germany

Related
1 trials

Shared therapeutic areas:

Allan-Herndon-Dudley Syndrome
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT05579327Phase 3PrincipalInvestigator

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

Allan-Herndon-Dudley SyndromeMonocarboxylate Transporter 8 Deficiency
Completed

All 1 trials loaded